CN106581002A - Antitumor drug vandetanib composition particles - Google Patents
Antitumor drug vandetanib composition particles Download PDFInfo
- Publication number
- CN106581002A CN106581002A CN201610982617.7A CN201610982617A CN106581002A CN 106581002 A CN106581002 A CN 106581002A CN 201610982617 A CN201610982617 A CN 201610982617A CN 106581002 A CN106581002 A CN 106581002A
- Authority
- CN
- China
- Prior art keywords
- cane sugar
- composition grain
- grain
- composition
- vandetanib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses antitumor drug vandetanib composition particles, and belongs to the technical field of medicine. The composition particles are composed of vandetanib and sugar powder, vandetanib is a new crystal compound, the X-ray powder diffraction pattern, obtained through Cu-Ka ray measurement, of vandetanib is shown in the figure 1, vandetanib is different from that reported by in the prior art, it is found through tests that the compound of a new crystal structure has obviously improved hygroscopicity and is low in impurity content and high in stability, and water solubility is improved. The particle agent made of the crystal compound is simple in composition, low in impurity content and high in stability.
Description
Technical field
The invention belongs to pharmaceutical technology field, is related to a kind of antineoplastic ZD6474 composition grain.
Background technology
ZD6474（Vandetanib）It is a kind of multiple receptor tyrosine kinases inhibitor, belongs to aniline quinazoline class chemical combination
Thing, is claimed " two generation Iressas ", acts not only on EGFR, VEGFR and RET EGFR-TK of tumour cell, be may also suppress
Other EGFR-TKs and serine/threonine kinase.ZD6474 is the medullary thyroid carcinoma of first approval
（medullary thyroid cancer）Medicine, it is adaptable to treatment can not cut off, Locally Advanced or have metastasis symptom or
The medullary thyroid carcinoma of progress.
Vandetanib chemical names are：4- (4- bromo-2-fluoroanilinos) -6- methoxyl group -7- [(1- methyl piperidine -4-
Base) methoxyl group] quinazoline, molecular formula is C22H24BrFN4O2, molecular weight is 475.36.Chemical structural formula is as follows：
As it is known by the man skilled in the art that the polymorph of medicine have become drug research process and pharmaceutical production quality control and
Requisite important component part in detection process.Research polymorphic to medicine contributes to new drug compound biologically active
Select, be favorably improved bioavilability, promote clinical efficacy, contribute to the selection and design of drug administration approach, and medicine
The determination of thing preparation process parameter, so as to improve pharmaceutical production quality.Same medicine crystalline form is different, and its bioavilability may be poor
It is different notable.Same medicine, some crystalline forms may possess higher biologically active than other crystalline forms.
At present, the patent that the crystal formation research with regard to ZD6474 has been disclosed for is as follows：
Patent CN200680036335.2（One hydration 4- (4- bromo-2-fluoroanilinos) -6- methoxyl group -7- (1- methyl piperidine -4-
Ylmethoxy) quinazoline）Disclose the preparation method of a hydration ZD6474 and a hydration ZD6474, comprising an all moral of hydration
His Buddhist nun is used for manufacture and produces in vivo in warm-blooded animal (such as the mankind) as the pharmaceutical composition of active component, a hydration ZD6474
The purposes of the medicine of Anti- angiogenesis and/or reduction vascular permeability effect, a hydration ZD6474 are treating warm-blooded animal (such as
The mankind) related to the vascular permeability of Angiogenesiss and/or raising in vivo symptom (such as cancer) method in purposes.It is said
The anhydrous form and monohydrate form of ZD6474, the wherein most significant X-ray in the 10 of anhydrous form are disclosed in bright book
The θ angles of powder diffraction peak 2 are respectively：15.0、21.4、23.3、20.7、18.9、18.1、23.7、8.3、22.1、29.5；One water
The most significant θ angles of X-ray powder diffraction peak 2 of 10 of solvate form are respectively：10.8、21.0、18.4、11.9、18.9、
18.1、22.1、11.4、20.1、24.0。
Patent CN200680036468.X（Chemical method）Disclose and prepare some quinazoline derivants or its pharmacy and can connect
The chemical method of the salt received and the method for preparing some intermediates for preparing quinazoline derivant, and using the intermediate
Method to prepare quinazoline derivant.Particularly it is used for prepare compound 4- (4- bromo-2-fluoroanilinos) -6- methoxyl group -7-
The chemical method and intermediate of (1- methyl piperidine -4- ylmethoxies) quinazoline.Its specification embodiment 19 is disclosed by this
Ten X-ray powder diffraction peaks for most protruding of the anhydrous ZD6474 of bright method synthesis, its 2 θ angle is respectively：15.0、
21.4、23.3、20.7、18.9、18.1、23.7、8.3、22.1、29.5。
The present inventor starts with from the research of ZD6474 solid chemical material existence, prepares through substantial amounts of test
A kind of new ZD6474 crystalline compounds, surprisingly find through test, and the compound of the new crystal structure has and substantially changes
Kind hygroscopicity, improves water solubility, and impurity content is low, good stability.Constituted using granule made by the crystalline compounds
Simply, impurity content is low, good stability.
The content of the invention
The goal of the invention of the present invention is to provide a kind of antineoplastic ZD6474 composition grain.
In order to complete the purpose of the present invention, the technical scheme for adopting for：
A kind of antineoplastic ZD6474 composition grain, is made up of ZD6474, cane sugar powder；Described ZD6474 is crystalline substance
Body, the X-ray powder diffraction figure obtained using Cu-K alpha ray measurements is as shown in Figure 1.
Preferably, in parts by weight, described ZD6474 composition grain by 125 weight portions ZD6474,
The cane sugar powder composition of 700-800 weight portions.
Preferably, in parts by weight, described ZD6474 composition grain by 125 weight portions ZD6474,750
The cane sugar powder composition of weight portion.
The preparation method of the antineoplastic ZD6474 composition grain is comprised the following steps：
1）ZD6474 is crossed into 60 mesh sieves, observation after sieving has foreign；
2）Cane sugar powder is crossed into 80 mesh sieves, foreign matter is checked for；
3）Configuration volume fraction is 95% ethanol（Wetting agent）, ZD6474 is mixed with cane sugar powder, use high-speed mixing granulating machine
High speed is dry-mixed 10 minutes, is well mixed, and adds configured good wetting agent wet mixing 3 minutes；
4）Particle is released, is pelletized with oscillating granulator, obtained final product；
5）Then mixed material is proceeded to into ebullated dryer to be dried, in dry run temperature control at 65 DEG C, drying time
For 25-30 minutes；
6）By dry particl pelletizing machine whole grain, sieve, weed out fine powder；
7）Dry particl after sieving suction feeding adds mixer mixing, it is mixed after hand over terminal, with pouch-packaged, then
External packing is carried out according to instruction.
The preparation method of the ZD6474 crystal in the present invention is comprised the following steps：
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, the mixed solvent of ethyl acetate, carbon tetrachloride is subsequently adding, is stirred
After uniform, stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding third
Ketone, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, filters, and obtains ZD6474 after vacuum drying 4-6 hours brilliant
Body.
In the present invention, described ZD6474 crude product is ZD6474 solid mixture to be further purified.Fan Deta
Buddhist nun's crude product can be prepared by art methods or additive method is obtained.
In the preparation method of the ZD6474 crystal of the present invention, the ethyl acetate, the body of the mixed solvent of carbon tetrachloride
Product is the 40%-60% of ZD6474 crude product saturated aqueous solution volume.The ethyl acetate, the volume ratio of carbon tetrachloride are 2:1.Institute
State acetone volume be ethyl acetate, 4-6 times of the mixed solvent volume of carbon tetrachloride.
Compared with prior art, the invention has the advantages that：
（1）ZD6474 crystal provided by the present invention is a kind of ZD6474 crystal different from prior art, the crystal energy
Solubility of the ZD6474 in water, and good fluidity are significantly improved, moisture absorption is difficult；
（2）ZD6474 crystal provided by the present invention has bioavilability height, drug effect is notable, stability is high, high income, pure
The advantages of spending high, contributes to the selection design and the determination of pharmaceutical preparation technology parameter of drug administration approach, so as to improve medicine
The product quality of production；
（3）The preparation method of ZD6474 crystalline compounds provided by the present invention is easy to operate, is a kind of economically feasible, is adapted to
The method of industrialized production；
（4）Granule containing ZD6474 crystal composition provided by the present invention is simple, impurity content is low, good stability.
Description of the drawings
Fig. 1 is the X-ray powder diffraction collection of ZD6474 crystal prepared by the embodiment of the present invention 1；
Fig. 2 is the heat analysis collection of illustrative plates of ZD6474 crystalline compounds shown in Fig. 1.
Specific embodiment
The content of the invention of the present invention is described in further detail below by specific embodiment, but is not therefore limited
Determine present disclosure.
Embodiment 1：The preparation of ZD6474 crystal
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, ZD6474 crude product saturated aqueous solution volume 40% is subsequently adding
The mixed solvent of ethyl acetate, carbon tetrachloride, described ethyl acetate, the volume ratio of carbon tetrachloride are 2:1, after stirring,
Stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding volume to be acetic acid
The acetone of ethyl ester, 4 times of the mixed solvent volume of carbon tetrachloride, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, mistake
Filter, after vacuum drying 4-6 hours ZD6474 crystal is obtained.
Obtained ZD6474 crystalline compounds are existed with the X-ray powder diffraction collection that the 2 θ ± 0.2 ° angles of diffraction are represented
3.3 °, 7.5 °, 8.3 °, 10.7 °, 20.2 °, 20.9 °, 23.5 °, 29.0 °, 30.4 °, show characteristic diffraction peak at 32.8 °, make
X-ray powder diffraction pattern as shown in Figure 1 is obtained with Cu-K alpha ray measurements, high-performance liquid chromatogram determination its purity is
99.9%.Carefully contrasted with the X-ray powder diffraction collection of each crystal formation of prior art, hence it is evident that find ZD6474 of the present invention
Crystalline compounds are different from prior art.
Determined using cassette moisture teller, the water content of the ZD6474 crystalline compounds of the present invention is 0.37%, therefore this
The crystalline compounds of invention do not contain the crystallization water.
Obtained ZD6474 crystalline compounds are adopted into Perkin-Elmer companies of U.S. PE Pyris Diamond
The thermogravimetric analysis figure that TG thermal analyzers are obtained is as shown in Figure 2.
Embodiment 2：The preparation of ZD6474 crystal
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, ZD6474 crude product saturated aqueous solution volume 50% is subsequently adding
The mixed solvent of ethyl acetate, carbon tetrachloride, described ethyl acetate, the volume ratio of carbon tetrachloride are 2:1, after stirring,
Stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding volume to be acetic acid
The acetone of ethyl ester, 5 times of the mixed solvent volume of carbon tetrachloride, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, mistake
Filter, after vacuum drying 4-6 hours ZD6474 crystal is obtained.
The X-ray powder diffraction spectrogram that obtained ZD6474 crystalline compounds are obtained using Cu-K alpha ray measurements with
Embodiment 1 is similar；The thermogravimetric point obtained using Perkin-Elmer companies of U.S. PE Pyris Diamond TG thermal analyzers
Analysis figure is similar to Example 1.
Embodiment 3：The preparation of ZD6474 crystal
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, ZD6474 crude product saturated aqueous solution volume 60% is subsequently adding
The mixed solvent of ethyl acetate, carbon tetrachloride, described ethyl acetate, the volume ratio of carbon tetrachloride are 2:1, after stirring,
Stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding volume to be acetic acid
The acetone of ethyl ester, 6 times of the mixed solvent volume of carbon tetrachloride, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, mistake
Filter, after vacuum drying 4-6 hours ZD6474 crystal is obtained.
The X-ray powder diffraction spectrogram that obtained ZD6474 crystalline compounds are obtained using Cu-K alpha ray measurements with
Embodiment 1 is similar；The thermogravimetric point obtained using Perkin-Elmer companies of U.S. PE Pyris Diamond TG thermal analyzers
Analysis figure is similar to Example 1.
Embodiment 4：The preparation of ZD6474 crystal
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, ZD6474 crude product saturated aqueous solution volume 40% is subsequently adding
The mixed solvent of ethyl acetate, carbon tetrachloride, described ethyl acetate, the volume ratio of carbon tetrachloride are 2:1, after stirring,
Stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding volume to be acetic acid
The acetone of ethyl ester, 5 times of the mixed solvent volume of carbon tetrachloride, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, mistake
Filter, after vacuum drying 4-6 hours ZD6474 crystal is obtained.
The X-ray powder diffraction spectrogram that obtained ZD6474 crystalline compounds are obtained using Cu-K alpha ray measurements with
Embodiment 1 is similar；The thermogravimetric point obtained using Perkin-Elmer companies of U.S. PE Pyris Diamond TG thermal analyzers
Analysis figure is similar to Example 1.
Embodiment 5：The preparation of ZD6474 crystal
55 DEG C of ZD6474 crude product saturated aqueous solution is prepared, ZD6474 crude product saturated aqueous solution volume 50% is subsequently adding
The mixed solvent of ethyl acetate, carbon tetrachloride, described ethyl acetate, the volume ratio of carbon tetrachloride are 2:1, after stirring,
Stir in cooling, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, while adding volume to be acetic acid
The acetone of ethyl ester, 6 times of the mixed solvent volume of carbon tetrachloride, stops stirring after being cooled to 0 DEG C, stand growing the grain 1-2 hours, mistake
Filter, after vacuum drying 4-6 hours ZD6474 crystal is obtained.
The X-ray powder diffraction spectrogram that obtained ZD6474 crystalline compounds are obtained using Cu-K alpha ray measurements with
Embodiment 1 is similar；The thermogravimetric point obtained using Perkin-Elmer companies of U.S. PE Pyris Diamond TG thermal analyzers
Analysis figure is similar to Example 1.
Example of formulations 1：The preparation of ZD6474 particle：
Raw material is constituted：125g ZD6474s and 700g cane sugar powders；
The ZD6474 is the ZD6474 crystal prepared by the embodiment of the present invention 1.
Preparation method：
1）ZD6474 crosses 60 mesh sieves, and observation after sieving has foreign；
2）Cane sugar powder crosses 80 mesh sieves, checks for foreign matter；
3）The ethanol of configuration volume fraction 95%（Wetting agent）, ZD6474 is mixed with cane sugar powder, it is high with high-speed mixing granulating machine
Rapid-curing cutback is mixed 10 minutes, is well mixed, and adds configured good wetting agent wet mixing 3 minutes；
4）Particle is released, is pelletized with oscillating granulator, obtained final product；
5）Then mixed material is proceeded to into ebullated dryer to be dried, in dry run temperature control at 65 DEG C, drying time
For 25-30 minutes；
6）By dry particl pelletizing machine whole grain, sieve, weed out fine powder；
7）Dry particl after sieving suction feeding adds mixer mixing, mixed rear friendship terminal to be distributed into pouch
1000 bags, then per bag of 0.125g containing ZD6474 carries out external packing according to instruction.
Example of formulations 2：The preparation of ZD6474 particle：
Raw material is constituted：125g ZD6474s and 700g cane sugar powders；
The ZD6474 is the ZD6474 crystal prepared by the embodiment of the present invention 2.
Preparation method：With example of formulations 1.
Example of formulations 3：The preparation of ZD6474 particle：
Raw material is constituted：125g ZD6474s and 700g cane sugar powders；
The ZD6474 is the ZD6474 crystal prepared by the embodiment of the present invention 3.
Preparation method：With example of formulations 1.
Example of formulations 4：The preparation of ZD6474 particle：
Raw material is constituted：125g ZD6474s and 700g cane sugar powders；
The ZD6474 is the ZD6474 crystal prepared by the embodiment of the present invention 4.
Preparation method：With example of formulations 1.
Example of formulations 5：The preparation of ZD6474 particle：
Raw material is constituted：125g ZD6474s and 700g cane sugar powders；
The ZD6474 is the ZD6474 crystal prepared by the embodiment of the present invention 5.
Preparation method：With example of formulations 1.
The present invention is further illustrated below by experimental example：
Trial target 1：ZD6474 crystalline compounds prepared by the embodiment of the present invention 1；
Trial target 2：ZD6474 crystalline compounds prepared by the embodiment of the present invention 4；
Reference substance 1：A hydration ZD6474 prepared by the embodiment 1 according to patent CN200680036335.2；
Reference substance 2：Embodiment 1 according to patent CN200680036468.X prepares anhydrous ZD6474；
Reference substance 3：Commercially available ZD6474 bulk drug.
Experimental example 1：Fluidity test
This experimental example evaluates the mobility of sample by the angle of repose of determination sample, and concrete grammar is as follows：Sample particle is taken, from
During the surface plate of circle is flowed in fixed little funnel, until obtaining highest cone, cone height H and radius R is measured,
Angle of repose α is calculated by tan α=H/R, 1 is the results are shown in Table, angle of repose is bigger, and mobility is poorer.
The fluidity test result of table 1
As known from Table 1, the ZD6474 crystalline compounds flowing compared with ZD6474 of the prior art, prepared by the present invention
Property is significantly improved, and is conducive to the preparation of preparation, dissolution rate, the raising of bioavilability.
Experimental example 2：Dissolubility test
Appropriate distilled water is added in the low capacity bottle with constant temperature jacket, ZD6474 is added at 25 DEG C to not re-dissolved
Till, start magnetic stirrer, persistently stir under constant temperature, in experimentation system all the time in two-phase coexistent state, 70
The concentration of ZD6474 solubility as at this temperature in the liquid phase of system after minute.Analysis is sampled after 2 hours, is taken
The close mean value of adjacent two times result as measured value of experiment, before sampling, in order that solid-liquid is sufficiently separated, after stopping stirring,
Not molten ZD6474 is deposited to the bottom of low capacity bottle, a small amount of upper clear supernate is extracted with syringe, with 0.45 micron of filter
Filter, sample is taken from filtrate, the content of ZD6474 is measured by HPLC（Concentration（mg/ml））.The results are shown in Table 2.
The water-soluble contrast of the new crystalline compounds of ZD6474 of the present invention and prior art crystal formation under the room temperature of table 2
From table 2 it can be seen that the water solubility of the new crystalline compounds of ZD6474 of the present invention is compared with prior art, has and significantly carry
It is high.
Experimental example 3：Draws moist test
What this experimental example had investigated the ZD6474 crystalline compounds of offer of the present invention draws moist, according to Chinese Pharmacopoeia 2010 editions two
Portion's annex XIXJ medicine draws moist test guidelines are carried out, and set the temperature of growth cabinet as 25 DEG C, and relative humidity is 95%
, the results are shown in Table 3.
Table 3：Draws moist test result
From table 3 it can be seen that compared with the ZD6474 crystalline compounds of prior art, ZD6474 crystalline compounds of the present invention
For non-hygroscopic, its stability under high humidity environment is substantially better than using the ZD6474 of prior art.
Experimental example 4：Influence factor is tested
By trial target and reference substance simulation listing packaging, in 60 DEG C of high temperature, illumination 4500Lx, high humidity（RH90%±5%）Under the conditions of
Place 10 days, detected by stability high spot reviews project, compare with 0 day sample, the results are shown in Table 4.
The influence factor result of the test of table 4
The height of drug quality is directly connected to the health of millions upon millions of working people's bodies, be also related to China's economic construction into
Effect, the consolidation of national defence and nationality it is flourishing；It has been far from the thing of medical industry enterprise scope itself, but the whole people
Race, the major issue in the world.Those skilled in the art clearly know that, in the present age that pharmaceutical technology is flourishing, drug safety standard is not by
Disconnected to be lifted, the purity of prepared medicine also more and more higher is effectively reduced impurity content, even several percentage points of zero point,
The generation of bad reaction can also be effectively reduced, therefore impurity content is most important to drug quality and people's drug safety.
Medicine needs to store and transport just to cure the sickness to save the patient from production in the process of circulation, therefore, medicine in storage and transportation
Quality is particularly important, and stability is the key for determining drug quality quality, in medicine storage and transportation, stability
Bad, impurity change directly affects greatly people's drug safety.
As can be seen from the above table, list using ZD6474 crystalline compounds obtained in the method for the present invention is miscellaneous, total miscellaneous etc.
Content is very low, and stability is significantly better than the ZD6474 of prior art, effectively improves drug safety and storage
Stability, reduces the generation of bad reaction.
Above-mentioned experimental example 1-4 has been also carried out to the ZD6474 crystalline compounds of other embodiments of the present invention, what it was obtained
As a result it is similar.
Experimental example 5：Preparation influence factor is tested
Formulation test product 1：ZD6474 particle prepared by invention formulation embodiment 1；
Formulation test product 2：ZD6474 particle prepared by invention formulation embodiment 2.
By formulation test product simulation listing packaging, in 60 DEG C of high temperature, illumination 4500Lx, high humidity（RH90%±5%）Under the conditions of
Place 10 days, detected by stability high spot reviews project, compare with 0 day sample, the results are shown in Table 5.
The preparation influence factor result of the test of table 5
Found by result above, the composition grain impurity content containing the ZD6474 crystalline compounds prepared by the present invention
It is low, good stability.
Above-mentioned test is also carried out to the ZD6474 particle of other example of formulations of the invention, its result phase for obtaining
Seemingly.
Claims (4)
1. a kind of antineoplastic ZD6474 composition grain, it is characterised in that：Described composition grain is by ZD6474
With cane sugar powder composition；Described ZD6474 is crystal, the X-ray powder diffraction figure such as figure obtained using Cu-K alpha ray measurements
Shown in 1.
2. antineoplastic ZD6474 composition grain according to claim 1, it is characterised in that：In parts by weight,
Described composition grain is made up of the ZD6474 of 125 weight portions, the cane sugar powder of 700-800 weight portions.
3. antineoplastic ZD6474 composition grain according to claim 2, it is characterised in that：In parts by weight,
Described composition grain is made up of the ZD6474 of 125 weight portions, the cane sugar powder of 750 weight portions.
4. according to the arbitrary described antineoplastic ZD6474 composition grain of claim 1-3, it is characterised in that described
The preparation method of composition grain is comprised the following steps：
1）ZD6474 is crossed into 60 mesh sieves, observation after sieving has foreign；
2）Cane sugar powder is crossed into 80 mesh sieves, foreign matter is checked for；
3）Configuration wetting agent, ZD6474 is mixed with cane sugar powder, and dry-mixed 10 minutes with high-speed mixing granulating machine high speed, mixing is equal
It is even, add configured good wetting agent wet mixing 3 minutes；Described wetting agent is ethanol that volume fraction is 95%；
4）Particle is released, is pelletized with oscillating granulator, obtained final product；
5）Then mixed material is proceeded to into ebullated dryer to be dried, in dry run temperature control at 65 DEG C, drying time
For 25-30 minutes；
6）By dry particl pelletizing machine whole grain, sieve, weed out fine powder；
7）Dry particl after sieving suction feeding adds mixer mixing, it is mixed after hand over terminal, with pouch-packaged, then
External packing is carried out according to instruction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982617.7A CN106581002A (en) | 2016-11-09 | 2016-11-09 | Antitumor drug vandetanib composition particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982617.7A CN106581002A (en) | 2016-11-09 | 2016-11-09 | Antitumor drug vandetanib composition particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581002A true CN106581002A (en) | 2017-04-26 |
Family
ID=58590675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610982617.7A Pending CN106581002A (en) | 2016-11-09 | 2016-11-09 | Antitumor drug vandetanib composition particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581002A (en) |
-
2016
- 2016-11-09 CN CN201610982617.7A patent/CN106581002A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7253491B2 (en) | Crystal Polymorph of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, and Method for Producing and Application of Same | |
| WO2021227146A1 (en) | N-[8-(2-hydroxybenzoyl)amino]monopotassium octanoate crystal compound, and preparation method therefor and use thereof | |
| CN110128356A (en) | A kind of Gefitinib and 3- hydroxybenzoic acid eutectic | |
| CN106349192B (en) | The eutectic of orlistat and amino acid and include eutectiferous pharmaceutical composition | |
| CN111565708B (en) | Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative | |
| CN110156700A (en) | Gefitinib and salicylic acid eutectic | |
| CN105193749A (en) | Medicinal tadalafil composition tablets for treating urological diseases | |
| CN106581002A (en) | Antitumor drug vandetanib composition particles | |
| CN106588880A (en) | Antitumor drug vandetanib compound | |
| CN106588879A (en) | Method for preparing antitumor drug vandetanib compound | |
| CN111454221B (en) | Gefitinib and bumetanide drug cocrystal and preparation method thereof | |
| CN111689947B (en) | tegafur-L-proline co-crystal and preparation method thereof | |
| JP2023510684A (en) | Lenvatinib Mesylate Crystalline Form XI and Process for its Preparation | |
| CN103804366B (en) | Lafutidine crystal compound | |
| CN106478598B (en) | A kind of Vande Thani hydrate crystal and preparation method thereof | |
| CN105106139A (en) | Medicine of tadalafil composition particles for treating urinary surgery diseases | |
| CN109456293A (en) | Apiolin -4,4 '-bipyridyl eutectic and preparation method thereof | |
| CN109516991A (en) | A kind of citric acid tropsch imatinib crystal-form compound and preparation method thereof | |
| CN106588882A (en) | Vandetanib compound for Vandetanib composition dry suspension as antitumor drug | |
| CN106619642A (en) | Composition dry suspension of anti-tumor medicine Vandetanib | |
| CN106588883A (en) | Method for preparing vandetanib compound applied in antitumor drug vandetanib composition capsule | |
| CN106588881A (en) | Method for preparing Vandetanib compound used for Vandetanib composition dry suspension serving as anti-tumor drug | |
| CN106397401B (en) | A kind of crystalline compounds of anticancer drug and preparation method thereof | |
| WO2024002127A1 (en) | Anti-tumor paclitaxel compound | |
| CN106632255A (en) | Vandetanib compound for anti-tumor medicine vandetanib composition capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170426 |